Article
HIF-independent actions of HIF-prolyl hydroxylase inhibitors reveal off-target pathways with therapeutic implications
2026-01-14
Abstract excerpt
<title>Abstract</title> <p>HIF-prolyl hydroxylase inhibitors (HIF-PHIs) are used to treat anemia in chronic kidney disease. These drugs stabilize hypoxia-inducible factors HIF-1α and HIF-2α, which activate erythropoiesis and iron metabolism pathways. Clinically approved HIF-PHIs such as roxadustat and molidustat exhibit distinct molecular structures and selectivity profiles, yet their HIF-independent effects rema...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- aed59544-f3d7-5d98-81a4-dc4d1928a6f0
- DOI
- 10.21203/rs.3.rs-8582402/v1
